psq.p

P Squared Renewables Inc. Announces Change of Name to Universal Ibogaine Inc.

 

(TheNewswire)

   

September 17, 2021 TheNewswire - Calgary, Alberta - P Squared Renewables Inc. (TSXV:PSQ.P) (" PSQ ") announces that as part of the completion of its recently announced Qualifying Transaction (the " QT ", as such term is defined under Policy 2.3 of the Corporate Finance Manual of the TSX Venture Exchange) it has formally changed its name to Universal Ibogaine Inc.

 

  As noted in PSQ's news release of September 2, 2021, the QT involved a three cornered Amalgamation   among PSQ, 1266855 B.C. Ltd. ("   Subco   ", a wholly owned subsidiary of PSQ), and Universal Ibogaine Inc. ("   UI   ").  

 

  The continuing entity (the "   Resulting Issuer   ") has now completed a formal name change to "Universal Ibogaine Inc." while UI and Subco Amalgamated on August 31, 2021 and continue as a B.C. corporation which was renamed "Clear Sky Recovery Solutions Inc.", which is a wholly owned subsidiary of UI.  

 

  Final TSXV Approval and Resumption of Trading  

 

  The ultimate listing of the common shares of the Resulting Issuer UI is subject to final approval by the TSXV, and resumption of trading of the common shares (under the intended trading symbol "IBO") is subject to TSXV conditions which UI is in process of completing, prior to the expected issuance in the coming weeks of the ultimate Final Exchange Bulletin by the TSXV.  

 

  NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.  

 

  CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS  

 

  ‎This news release contains forward-looking statements and information. More particularly, this ‎document contains statements and information relating to the QT that remains subject to final submissions and approval from the TSXV, as well as the intended name change . Forward-looking information is frequently characterized by words such ‎as "plan", "expect", "project", "intend", "will", "believe", "anticipate", "estimate", "scheduled", ‎‎"potential", or other similar words, or statements that certain events or conditions "may", "should" or ‎‎"could" occur.  The forward-looking statements and information are based on certain key expectations ‎and assumptions made by UI, including expectations and assumptions concerning timing of ‎receipt of required regulatory approval and the satisfaction of other conditions to the completion of ‎ the QT. Although UI believes that the expectations and assumptions on which the forward-‎looking statements are based are reasonable, undue reliance should not be placed on the forward-‎looking statements because UI can give no assurance that they will prove to be correct.  

 

  Since ‎forward-looking statements address future events and conditions, by their very nature they involve ‎inherent risks and uncertainties. Actual results could differ materially from those currently anticipated ‎due to a number of factors and risks, which include, but are not limited to, risks that required ‎regulatory approvals are not obtained. The reader is cautioned that assumptions used in the ‎preparation of such information, although considered reasonable by UI at the time of ‎preparation, may prove to be incorrect and readers are cautioned not to place undue reliance on ‎forward-looking information, which speaks only to conditions as of the date hereof.  UI does not ‎undertake any obligation to release publicly any revisions to forward-looking information contained ‎herein to reflect events or circumstances that occur after the date hereof or to reflect the occurrence ‎of unanticipated events, except as may be required under applicable securities laws. ‎  

 

‎‎ For further information regarding the Transaction, please contact:  

 

  Rami Batal        Shabir Premji  

 

  Chief Executive Officer        Former Executive Chairman & CEO  

 

  Universal Ibogaine Inc.        P Squared Renewables Inc.  

 

  Telephone: 416-902-4090        Telephone: 403-870-1841  

 

  Email: Rami.Batal@universalibogaine.com        Email:    spremji@p2renewables.com   

 

  NOT FOR DISSEMINATION IN THE UNITED STATES
OR THROUGH U.S. NEWS WIRES
 

 

Copyright (c) 2021 TheNewswire - All rights reserved.

 

News Provided by TheNewsWire via QuoteMedia

The Conversation (0)
Stethoscope on stacked gold coins, symbolizing healthcare costs or medical finance.

Trump Tariffs to Raise US Medical Device Costs, Hospitals Hold Off on Stockpiling

President Donald Trump’s new round of tariffs —this time targeting copper— has intensified concerns about rising costs across key sectors, including healthcare.

But despite significant price pressures on steel, aluminum, and now copper, all vital to medical device production, there is no indication that US hospitals are stockpiling equipment ahead of expected price hikes, according to recent findings from GlobalData.

Keep reading...Show less
Actinogen

Actinogen confirms 100th participant in XanaMIA phase 2b/3 Alzheimer’s disease trial and interim analysis timeline

Actinogen Medical ASX: ACW (“ACW” or “the Company”) is pleased to announce that the 100th participant in its pivotal XanaMIA phase 2b/3 randomized trial of Xanamem® for Alzheimer’s disease (AD) has now passed all screening tests and is scheduled for randomization and treatment in July. This establishes the timeline for the planned safety and efficacy futility interim analysis by an independent Data Monitoring Committee (DMC).

Keep reading...Show less
Emyria Limited

Medibank to Fund Emyria’s PTSD Program at Perth Clinic

Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”) a leader in developing and delivering innovative mental health treatments, is pleased to announce that Medibank Private Limited (“Medibank”), Australia’s largest private health insurer, has commenced funding for eligible customers to access Emyria’s Empax PTSD care program delivered in association with Perth Clinic.

Keep reading...Show less
ASX:HIQ

HITIQ Announces Exclusive Global Agreement with Shock Doctor for PROTEQT Instrumented Mouthguard

Common Shareholder Questions – Entitlement Offer

HITIQ Limited (ASX: HIQ) (HITIQ or the Company), a pioneer in concussion management, proudly announces an exclusive global agreement with Shock Doctor, the world’s leading mouthguard innovator. This landmark agreement marks Shock Doctor’s two-year effort to design a mouthguard that will integrate HITIQ’s PROTEQT technology. The result is a fully developed, market-ready solution that merges HITIQ’s smart sensor technology with Shock Doctor’s unmatched global production partner capabilities.

Keep reading...Show less
HeartSciences Inc

HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis

Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems

Keep reading...Show less
Zoono Group

Exclusive UK Packaging Agreement signed between Sharpak Aylesham Limited, Zoono, and OSY

Zoono Group Limited (Company) (ASX: ZNO) is pleased to update the market on an exclusive contract signed with Sharpak Aylesham Limited (Sharpak) and the Company’s partner in the food supply chain sector, OSY Group Limited (OSY).

Keep reading...Show less

Latest Press Releases

Related News

×